loading
Arcutis Biotherapeutics Inc stock is traded at $14.67, with a volume of 1.69M. It is down -5.23% in the last 24 hours and up +7.32% over the past month. Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$15.48
Open:
$15.65
24h Volume:
1.69M
Relative Volume:
0.90
Market Cap:
$1.75B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-3.7423
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
-2.27%
1M Performance:
+7.32%
6M Performance:
+15.69%
1Y Performance:
+50.15%
1-Day Range:
Value
$14.36
$15.78
1-Week Range:
Value
$14.36
$15.96
52-Week Range:
Value
$7.86
$17.75

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name
Name
Arcutis Biotherapeutics Inc
Name
Phone
805-418-5006
Name
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Name
Employee
342
Name
Twitter
@ArcutisBio
Name
Next Earnings Date
2024-12-06
Name
Latest SEC Filings
Name
ARQT's Discussions on Twitter

Compare ARQT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ARQT
Arcutis Biotherapeutics Inc
14.67 1.79B 59.61M -262.14M -247.49M -3.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.81 120.40B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
542.52 61.30B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.53 41.06B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
564.59 34.29B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.55 27.09B 3.81B -644.79M -669.77M -6.24

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-30-24 Initiated H.C. Wainwright Buy
Aug-28-24 Initiated Jefferies Buy
Jan-03-24 Upgrade Mizuho Neutral → Buy
Oct-26-23 Downgrade Mizuho Buy → Neutral
Oct-13-23 Downgrade Goldman Buy → Neutral
Sep-07-22 Initiated Needham Buy
Mar-17-22 Initiated Goldman Buy
Jun-30-21 Initiated Mizuho Buy
May-27-21 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-09-20 Upgrade Goldman Neutral → Buy
Oct-08-20 Initiated Truist Buy
Feb-25-20 Initiated Cantor Fitzgerald Overweight
Feb-25-20 Initiated Cowen Outperform
Feb-25-20 Initiated Goldman Neutral
Feb-25-20 Initiated Guggenheim Buy
View All

Arcutis Biotherapeutics Inc Stock (ARQT) Latest News

pulisher
05:53 AM

What analysts say about Arcutis Biotherapeutics Inc. stockExplosive portfolio gains - Jammu Links News

05:53 AM
pulisher
02:20 AM

What drives Arcutis Biotherapeutics Inc. stock priceHigh-impact stock picks - Jammu Links News

02:20 AM
pulisher
Jul 18, 2025

Arcutis Biotherapeutics Inc. Stock Analysis and ForecastConsistently superior profits - Jammu Links News

Jul 18, 2025
pulisher
Jul 18, 2025

Is Arcutis Biotherapeutics Inc. a good long term investmentTriple-digit wealth increases - Jammu Links News

Jul 18, 2025
pulisher
Jul 17, 2025

Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study - TipRanks

Jul 17, 2025
pulisher
Jul 15, 2025

Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load? - simplywall.st

Jul 15, 2025
pulisher
Jul 14, 2025

Arcutis Bio EVP Burnett sells $432k in ARQT stock after option exercise - Investing.com Canada

Jul 14, 2025
pulisher
Jul 14, 2025

Arcutis’ ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis - MSN

Jul 14, 2025
pulisher
Jul 11, 2025

FDA News and Decisions: Midyear Updates - Dermatology Times

Jul 11, 2025
pulisher
Jul 10, 2025

Arcutis Biotherapeutics Stock Scores RS Rating Upgrade - MSN

Jul 10, 2025
pulisher
Jul 09, 2025

Arcutis Biotherapeutics - WBFF

Jul 09, 2025
pulisher
Jul 09, 2025

Uncovering Plaque Psoriasis: Exploring New FDA-Approved Topical Treatment - ABC Action News

Jul 09, 2025
pulisher
Jul 04, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 04, 2025
pulisher
Jul 03, 2025

Morgan Stanley assumes coverage of Arcutis Biotherapeutics stock with Overweight rating - Investing.com Nigeria

Jul 03, 2025
pulisher
Jul 03, 2025

Arcutis Awards Generous Stock Compensation Package: 14,000 RSUs for Two New Hires - Stock Titan

Jul 03, 2025
pulisher
Jun 27, 2025

Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis - Contemporary Pediatrics

Jun 27, 2025
pulisher
Jun 26, 2025

Arcutis Biotherapeutics (ARQT) Gains Strong AAD Recommendation for ZORYVE Cream | ARQT Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

ZORYVE Becomes Only Branded Topical to Earn Strong AAD Recommendation for Atopic Dermatitis - Stock Titan

Jun 26, 2025
pulisher
Jun 25, 2025

Arcutis Biotherapeutics: Another Approval Under Their Belt - Seeking Alpha

Jun 25, 2025
pulisher
Jun 18, 2025

When (ARQT) Moves Investors should Listen - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 18, 2025

Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long - Yahoo Finance

Jun 18, 2025
pulisher
Jun 17, 2025

Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks

Jun 17, 2025
pulisher
Jun 12, 2025

Arcutis: Out Of The Woods, Ready For Commercialization - Seeking Alpha

Jun 12, 2025
pulisher
Jun 11, 2025

10 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Australia

Jun 10, 2025
pulisher
Jun 10, 2025

Arcutis Biotherapeutics (ARQT) Begins Trial for Infant Atopic De - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis - Taiwan News

Jun 10, 2025
pulisher
Jun 10, 2025

Breakthrough: New Eczema Treatment Trial Launches for 3-Month-Old Infants, Targeting 9.6M Children - Stock Titan

Jun 10, 2025
pulisher
Jun 09, 2025

Arcutis says Zoryve data demonstrates durable atopic dermatitis improvements - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

H.C. Wainwright maintains $19 target on Arcutis stock - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

H.C. Wainwright maintains $19 target on Arcutis stock By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 08, 2025

Wellington Management Group LLP Sells 3,882 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq L - GuruFocus

Jun 07, 2025
pulisher
Jun 06, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ARQT Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com

Jun 06, 2025
pulisher
Jun 06, 2025

Arcutis Grants 72,000 Restricted Stock Units to 9 New Hires: Key Details on 4-Year Vesting Plan - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

Arcutis Presents Long-Term INTEGUMENT-OLE Data on Roflumilast at RAD 2025 - Dermatology Times

Jun 06, 2025
pulisher
Jun 06, 2025

Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis - Benzinga

Jun 06, 2025
pulisher
Jun 06, 2025

Road to RAD: What to Expect - Dermatology Times

Jun 06, 2025
pulisher
Jun 06, 2025

ARQT Reveals Promising Long-Term Data for Zoryve in Atopic Derma - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Arcutis Biotherapeutics director Heron buys $30,246 in stock By Investing.com - Investing.com India

Jun 06, 2025

Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.88
price down icon 0.59%
$35.59
price up icon 0.34%
$102.56
price down icon 1.55%
$26.20
price down icon 5.18%
$110.02
price down icon 0.92%
biotechnology ONC
$294.55
price up icon 1.45%
Cap:     |  Volume (24h):